|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contributor Cindy H. Dubin speaks with several innovative companies to highlight the strides they are currently making toward improving dose accuracy, integrating design safety, and accelerating time to market.
|
|
|
Denis Dufrane, MD, PhD, Chief Executive Officer, and Founder of Novadip Biosciences, discusses his company’s innovative approach to tissue regeneration technology.
|
|
|
Zach Fletcher explains how an experienced manufacturing partner can help therapy developers quickly identify solutions and develop manufacturing and formulation methods for use in many applications.
|
|
|
Paul Radspinner, MBA, and Pamuk Bilsel, PhD, say with a combination vaccination strategy, the biopharma industry could truly solve the efficacy, durability, and drift problems of current influenza and COVID-19 vaccines.
|
|
|
|
|
|
|
|
|

Mitsubishi Gas Chemical (MGC) is a leading company in the field of oxygen barrier and absorbing polymers. Based on these technologies and experiences, MGC launched new multilayer plastic vial named OXYCAPT in 2019. It has achieved excellent oxygen and ultraviolet (UV) barrier, high water vapor barrier, very low extractables, high pH stability, low protein adsorption, high transparency, high break resistance, easier disposability, lighter weight, etc. Click here for more.
|
|
|
|
|
|
 |
|
Cellular Origins recently announced a collaborative partnership with ScaleReady, a joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf that brings together process development expertise, tools, and technologies for scalable CGT….
|
|
 |
|
New collaboration combines Mekonos’ novel ex vivo delivery platform with bit.bio’s unique opti-ox™ precision cellular reprogramming technology to accelerate the development of human cells for research, drug discovery and….
|
|
 |
|
Evonetix recently announced DNA synthesized using its unique semiconductor chip technology was delivered to the Department of Chemical Engineering and Biotechnology at the University of Cambridge. This milestone marks the start of the next stage of development of the….
|
|
 |
|
Syneos Health, Inc. recently announced it has entered into a definitive agreement to be acquired by a consortium of private investment firm affiliates composed of Elliott Investment Management, Patient Square Capital….
|
|
|
|
|
|
|
|
 |
|
The effectiveness of inhalation devices relies on their ability to deliver the pharmaceutical directly to the targeted part of the body with precision and calculated dosing. Since these devices….
|
|
|
|
|
|
|
|
 |
|
Particle Works is thrilled to announce the launch of a new Application Note that delves into the advancement of nanoparticles as carriers for targeted drug delivery. Developing nanoparticles for this purpose can be intricate and demanding, necessitating consistent, cost-effective, and …
|
|
 |
|
A key focus of the U.S. Food and Drug Administration’s evaluation of a medical device’s safety and effectiveness is reviewing its material makeup. If improperly tested – and impure materials are used – there is an elevated risk of contamination …
|
|
 |
|
Aseptic processing with the highest degree of sterility assurance, filling accuracy, and quality is critical for high-value, small-batch therapies. This white paper explores the specialized equipment, expertise, and services needed for efficient biologics fill/finish manufacturing.
CLICK HERE TO DOWNLOAD/VIEW THE …
|
|
 |
|
Synchronizing and controlling API delivery, extrusion-spheronization (E-S) offers pharmaceutical companies a robust technique to manufacture today’s most complex therapeutics. Manufacturing oral solid dose (OSD) APIs into spheres via E-S is not new. What is new is that in the …
|
|
|
|
|
Upcoming eNewsletter Features:
May 24 – Parenteral Contract Manufacturing
May 31 – Controlled Release
|
|
|
|
|
|
|
|